Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Bullboard Posts
Comment by Righttothetopon Oct 27, 2020 12:44pm
56 Views
Post# 31788882

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Shorts will get smashed soon

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Shorts will get smashed soon Beyond that is that persons presuming the US will welcome this sector with open arms are delusional.  Just look at the politics...50/50 split, down the middle.  Yes, 50 want their weed/derivatives, but the other 50 believe it to be devil worship, so couple that with the teething pains that Lemoyne correctly points out, and LABS has prime-mover advantage.

And it's lunacy to suggest the German market is a puddle.  Germany and it's progressive society embraces alterative medicine in ways that the NA market does not...this is true for all Europe, so a deal with Stada doesn't just mean Germany, it means all of Europe.....Europe ain't no puddle and the fact that it will be openning up to LABS early 2021 means big time advantage.

Stada or Bain takes an equity stake by end of 2021 or in 2022.....I just hope by then our SP is reflective of our true potential.

Fladibabba has a clear motive here, as if he doesn't believe he'll get back to his average, then why not sell, plug your nose and move on?  Hmmmm....wonder why not?



Lemoyne wrote: So simpleminded. Every thing is guaranteed in your head and looks so easy. Everything you mention is possible but your timeline is so short. It took 2 years for Cad market to evolve and be bottlenecked and we are finally seeing some M&A talks. It's not because cannabis is legal that banks welcome them warmly.

It's gonna take years for everything you mentioned to happen, because banks won't shell out candy to every one so quickly. M&A's happening too soon will lead to overpaying for the hype (Remember something?). You think US market will be 100% functionnal and efficient from the start? LMAO. It's gonna be chaos. The same will happen as CAD and all other markets around the world. Businesses will pop everywhere trying to gobble up market share.

And that's once the MORE act is passed. Granted it could happen within the next year, but it could also take time because of COVID and other urgent matters.

And that's not even arguing about whether LABS will be outcompetitioned or not. STADA is in the US, why wouldn't they bolster up LABS? Take an equity stake? You think they signing a contract is for Germany only? You think they are blind to US market opportunity?

Take a good look at the big picture.


Bullboard Posts